Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

W81XWH-21-SRP-IDA: DoD Scleroderma, Idea Development Award

Closed Closed September 1, 2021 Opportunity W81XWH-21-SRP-IDA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2021.

• Total funding$1.9 million
• Expected awards3
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The IDA promotes ideas that are still in the early stages of development and have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative high-risk/high-reward research that could lead to critical discoveries or major advancements in scleroderma research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale. New Investigator Collaboration Option: The FY21 SRP IDA mechanism encourages applications in which a New Investigator in the early stages of their career partners with an established scleroderma researcher (as demonstrated by current funding and recent publications). The New Investigator Collaboration Option is designed to support the continued development of promising independent investigators that are early in their faculty appointments. All New Investigators must meet specific eligibility criteria as described in Section II.C, Eligibility Information. If the New Investigator Collaboration Option is selected, one PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Initiating PI must be a New Investigator. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. If recommended for funding, each PI will be named to an individual award within the recipient organization. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission. The following are significant features of the FY21 SRP IDA: • Preliminary Data: Preliminary data are required but need not be from the scleroderma research field. Preliminary data may include unpublished or published results from the laboratory of the PI or collaborators named on the application and/or data from the published literature relevant to scleroderma. • Impact: The application should describe the potential short-term impact of the research project toward improving the understanding of the causes and progression of scleroderma and/or realizing improvements in patient care and/or quality of life.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.